Risk of infection in <scp>MPN</scp> patients in the era of <scp>C</scp>ovid‐<scp>19</scp>: A prospective multicenter study of <scp>257</scp> patients from the <scp>CML‐MPN Q</scp>uebec <scp>R</scp>esearch <scp>G</scp>roup

Simpson-Poirier, Kevin; Harnois, Michaël; Olney, Harold J.; Sirhan, Shireen; Gratton, Michel-Olivier; Assouline, Sarit; Laneuville, Pierre; Delage, Robert; Mollica, Luigina; Busque, Lambert; Szuber, Natasha

doi:10.1002/ajh.26159

Cited by 3 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the main objective of MPN treatment is to control the overproduction of one or more types of BCs, emerging research has shown that MPN treatments can have unintended impacts on serum lipid concentrations of patients, potentially leading to dyslipidemia and MetS[ 67 ]. Dyslipidemia, a condition characterized by an abnormal amount of lipids in the blood, and MetS, a group of conditions including increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal TC or TG levels, have been increasingly reported as side effects of various MPN treatments.…”

Section: Management Of Dyslipidemia and Metabolic Syndrome In Mpns An...mentioning

confidence: 99%

Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms

Găman,

Srichawla,

Chen

et al. 2024

World J Clin Oncol

View full text Add to dashboard Cite

Myeloproliferative neoplasms (MPNs) occur due to the abnormal proliferation of one or more terminal myeloid cell lines in peripheral blood. Subjects suffering from MPNs display a high burden of cardiovascular risk factors, and thrombotic events are often the cause of death in this population of patients. Herein, we provide a brief overview of dyslipidemia and metabolic syndrome and their epidemiology in MPNs and examine the common molecular mechanisms between dyslipidemia, metabolic syndrome, and MPNs, with a special focus on cardiovascular risk, atherosclerosis, and thrombotic events. Furthermore, we investigate the impact of dyslipidemia and metabolic syndrome on the occurrence and survival of thrombosis in MPN patients, as well as the management of dyslipidemia in MPNs, and the impact of MPN treatment on serum lipid concentrations, particularly as side/adverse effects reported in the context of clinical trials.

show abstract

Section: Management Of Dyslipidemia and Metabolic Syndrome In Mpns An...mentioning

confidence: 99%

Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms

Găman,

Srichawla,

Chen

et al. 2024

World J Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Nonetheless, this survey suggests that adherence to basic prevention rules can reduce the risk of infection [ 36 ]. In a prospective study on 257 MPN patients from Canada, only 1% contracted COVID-19 infection, much less than would be expected given provincial infection rates [ 37 ]. In another survey conducted on 964 MPN patients from United Kingdom, 96.1% of respondents reported no previous confirmed COVID-19 infection; notably, 91.5% of respondents reported COVID-19 vaccination when they had the opportunity and only 0.8% of respondents declined offer of COVID-19 vaccination [ 38 ].…”

Section: Is the Risk Of Infection And Severe Sars-cov-2 Illness Higher In Mpn Patients?mentioning

confidence: 99%

Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios

Palandri

Breccia

Stefano

et al. 2021

Cancers

View full text Add to dashboard Cite

An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) started in December 2019 in China and then become pandemic in February 2020. Several publications investigated the possible increased rate of COVID-19 infection in hematological malignancies. Based on the published data, strategies for the management of chronic Philadelphia-negative chronic myeloproliferative neoplasms (MPNs) are provided. The risk of severe COVID-19 seems high in MPN, particularly in patients with essential thrombocythemia, but not negligible in myelofibrosis. MPN patients are at high risk of both thrombotic and hemorrhagic complications and this must be accounted in the case of COVID-19 deciding on a case-by-case basis. There are currently no data to suggest that hydroxyurea or interferon may influence the risk or severity of COVID-19 infection. Conversely, while the immunosuppressive activity of ruxolitinib might pose increased risk of infection, its abrupt discontinuation during COVID-19 syndrome is associated with worse outcome. All MPN patients should receive vaccine against COVID-19; reassuring data are available on efficacy of mRNA vaccines in MPNs.

show abstract

Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine

et al. 2022

View full text Add to dashboard Cite

Risk of infection in MPN patients in the era of Covid‐19: A prospective multicenter study of 257 patients from the CML‐MPN Quebec Research Group

Abstract: cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia.

Cited by 3 publications

References 6 publications

Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms

Overview of dyslipidemia and metabolic syndrome in myeloproliferative neoplasms

Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios

Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine

Contact Info

Product

Resources

About